secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2026-04-20T23:59:59+00:00
Accession:  0001193125-26-162755
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna Phase 2 miv-cel data shows 100% response rate at 24 weeks in gMG; durable to 52 weeks
--------------------------------------------------------------------------------

- 100% of 7 patients achieved ≥3-point reduction in MG-ADL and QMG (co-primary endpoints) at 24 weeks; mean reductions -8.5 and -11.3 points.
- 57% of patients achieved minimal symptom expression (MG-ADL 0 or 1) at last follow-up; responses deepened over time.
- 100% were free of nonsteroidal immunosuppressants, high-dose steroids, and FcRn/complement inhibitors through Week 24.
- No high-grade CRS or ICANS; two transient grade 3/4 neutropenia events resolved; safety supports outpatient administration.
- Median follow-up 10.2 months (range 3.3–16.0); company enrolling Phase 3 registrational trial across 14 sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526162755/0001193125-26-162755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526162755/kytx-20260420.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-162755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer